GlassScriptPhysician profile
Sarah Weekly
NPI 1962061564
$6,124.14
in general payments reported to CMS, 2019-2025
60 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $1,041 · 2023: $985 · 2024: $1,073 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,940 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.91 |
| Education | $127.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $594.23 | 2021-2025 | |
| Incyte Corporation | $375.47 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $369.43 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $321.38 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.70 | 2021-2024 | Iclusig, Alunbrig, Ninlaro |
| Glaxosmithkline, LLC. | $252.48 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $236.75 | 2021-2023 | Lumakras |
| Merck Sharp & Dohme LLC | $227.46 | 2021-2025 | Keytruda, Lynparza |
| Geron Corporation | $223.81 | 2024-2025 | Rytelo |
| Janssen Biotech, INC. | $205.77 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Genentech USA, INC. | $195.78 | 2021-2024 | Venclexta, Lunsumio, Polivy |
| Beigene USA, INC. | $195.33 | 2021-2025 | Brukinsa |
| Celgene Corporation | $176.92 | 2022-2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $142.55 | 2024-2025 | Enhertu, Datroway |
| Jazz Pharmaceuticals INC. | $115.14 | 2021-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $113.83 | 2025 | Brukinsa, Tevimbra |
| Springworks Therapeutics, INC. | $102.58 | 2024-2025 | Ogsiveo, Gomekli |
| Abbvie INC. | $98.45 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $97.49 | 2021-2023 | Imbruvica, Epkinly |
| Aveo Pharmaceuticals, INC. | $90.56 | 2023-2025 | Fotivda |
| Taiho Oncology, INC. | $84.11 | 2023-2025 | |
| Pfizer INC. | $81.76 | 2022-2025 | |
| Genzyme Corporation | $78.76 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $76.53 | 2021-2025 | Opdivo, Opdualag |
| Amneal Pharmaceuticals LLC | $73.54 | 2025 | Alymsys |
| Gilead Sciences, INC. | $68.29 | 2022-2025 | Trodelvy |
| Sobi, INC | $67.37 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $65.77 | 2022-2024 | Odomzo, Yonsa |
| Lilly USA, LLC | $65.28 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Mirati Therapeutics, INC. | $59.24 | 2023 | Krazati |
| Tersera Therapeutics LLC | $57.53 | 2023-2025 | Zoladex |
| Recordati_rare_diseases_inc. | $55.32 | 2023-2024 | Sylvant |
| Karyopharm Therapeutics INC. | $55.26 | 2022-2025 | Xpovio |
| Stemline Therapeutics INC. | $54.92 | 2023-2025 | Orserdu |
| Amag Pharmaceuticals, INC. | $54.38 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $53.81 | 2021-2024 | Onivyde |
| Coherus Oncology, INC. | $53.30 | 2021-2025 | Loqtorzi |
| Astellas Pharma US INC | $46.23 | 2024-2025 | Vyloy |
| Blueprint Medicines Corporation | $45.74 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $45.43 | 2022-2024 | |
| Exelixis INC. | $44.97 | 2025 | Cabometyx |
| Adc Therapeutics America, INC. | $42.55 | 2022-2024 | |
| Tempus Ai, INC | $40.46 | 2024-2025 | Xt Cdx |
| Genmab U.S., INC. | $39.25 | 2024-2025 | Tivdak |
| Adaptive Biotechnologies Corporation | $33.36 | 2025 | Clonoseq |
| Seagen INC. | $25.51 | 2021-2023 | Tukysa |
| Array Biopharma INC | $25.38 | 2025 | Braftovi, Lorbrena, Xalkori |
| Ge Healthcare | $25.38 | 2025 | |
| Octapharma USA, INC. | $24.74 | 2025 | Octagam Immune Globulin (Human) |
| Emd Serono, INC. | $20.63 | 2025 | |
| G1 Therapeutics, INC. | $19.57 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.45 | 2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $18.21 | 2023 | |
| Spectrum Pharmaceuticals INC. | $17.70 | 2025 | Rolvedon |
| Acrotech Biopharma INC. | $16.89 | 2021 | |
| Agios Pharmaceuticals, INC. | $16.56 | 2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $16.22 | 2023 | Qinlock |
| Pharmacosmos Therapeutics INC. | $15.01 | 2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $12.33 | 2021 | |
| Rigel Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Weekly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.